About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 134 record(s)
Req # A-2021-001069
Adverse Drug Reactions (ADRs) for ZOPICLONE. Report numbers: E2B_03521863, E2B_03524707, E2B_03773337, E2B_03598084, E2B_03915853, E2B_04023493, E2B_03912410, E2B_03844142, E2B_03579404, E2B_03538408.Organization: Health Canada
February 2022
Req # A-2021-001092
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 21-112762-980.Organization: Health Canada
February 2022
Req # A-2021-001136
Adverse Drug Reactions (ADRs) for CLOPIDOGREL BISULFATE. Report numbers: E2B_03753029, E2B_03600802, E2B_03765610, E2B_03864168, E2B_03971501, E2B_03680490.Organization: Health Canada
February 2022
Req # A-2021-001152
Adverse Drug Reaction (ADR) for LEFLUNOMIDE. Report number: E2B_03826853.Organization: Health Canada
February 2022
Req # A-2021-001153
Adverse Drug Reaction (ADR) for ANTI-THYMOCYTE GLOBULIN (RABBIT). Report number: E2B_03960400.Organization: Health Canada
February 2022
Req # A-2021-001188
Adverse Drug Reactions (ADRs) for Furosemide. Report numbers: 653339, 917022, 929796, 944427, 945885, E2B_02599371, E2B_02704591, E2B_04217039, E2B_03301156, E2B_03721637, 551390, 620030, 919565, 921593, 921901, 921918, 922329, 923965, 924989, 925315.Organization: Health Canada
February 2022
Req # A-2021-001189
Adverse Drug Reactions (ADRs) for Furosemide. Report numbers: E2B_03406733, E2B_03406743, E2B_03406809, E2B_03417586, E2B_03420394, E2B_03429750, E2B_03432787, E2B_03454053, E2B_03459572, E2B_03465970, E2B_03476650, E2B_03486667, E2B_03478436, E2B_03482481, E2B_03482529, E2B_03484777, E2B_03484971, E2B_03486669, E2B_03505079, E2B_03506446.Organization: Health Canada
February 2022
Req # A-2021-001191
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 21-111766-914, COVID-19 Mass Vaccination Advertising Campaign.Organization: Health Canada
February 2022
Req # A-2021-001207
Adverse Drug Reactions (ADRs) for Furosemide. Report numbers: E2B_03508344, E2B_03526341, E2B_03528819, E2B_03541719, E2B_03542638, E2B_03542646, E2B_03551339, E2B_03555323, E2B_03586517, E2B_03587052, E2B_03639641, E2B_03640889, E2B_03698040, E2B_03723458, E2B_03738509, E2B_03755570, E2B_03777898, E2B_03906061, E2B_03942773, E2B_03997152.Organization: Health Canada
February 2022
Req # A-2021-001214
Adverse Drug Reactions (ADRs) for Furosemide. Report numbers: E2B_04159604, E2B_04137972, E2B_04063204, E2B_04009172, E2B_03362614, E2B_03384585, E2B_03397866, E2B_03400650.Organization: Health Canada
February 2022